JP2009544740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544740A5 JP2009544740A5 JP2009522019A JP2009522019A JP2009544740A5 JP 2009544740 A5 JP2009544740 A5 JP 2009544740A5 JP 2009522019 A JP2009522019 A JP 2009522019A JP 2009522019 A JP2009522019 A JP 2009522019A JP 2009544740 A5 JP2009544740 A5 JP 2009544740A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- alkyl
- composition
- composition according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 14
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 14
- 210000001525 retina Anatomy 0.000 claims description 12
- 208000017442 Retinal disease Diseases 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 206010038848 Retinal detachment Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 230000000642 iatrogenic effect Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 230000005012 migration Effects 0.000 claims description 5
- 238000002428 photodynamic therapy Methods 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 230000004264 retinal detachment Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 208000034693 Laceration Diseases 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims description 4
- 229950002652 safinamide Drugs 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 238000002647 laser therapy Methods 0.000 claims description 2
- 238000013532 laser treatment Methods 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000327 mueller cell Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82073506P | 2006-07-28 | 2006-07-28 | |
| PCT/US2007/074603 WO2008014457A1 (en) | 2006-07-28 | 2007-07-27 | Monoamine oxidase inhibitors useful for treating disorders of the outer retina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544740A JP2009544740A (ja) | 2009-12-17 |
| JP2009544740A5 true JP2009544740A5 (enExample) | 2011-08-04 |
Family
ID=38743901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522019A Pending JP2009544740A (ja) | 2006-07-28 | 2007-07-27 | 網膜外層の障害を治療するためのモノアミンオキシダーゼ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110160308A1 (enExample) |
| EP (1) | EP2046451A1 (enExample) |
| JP (1) | JP2009544740A (enExample) |
| KR (1) | KR20090034365A (enExample) |
| CN (1) | CN101495185A (enExample) |
| AU (1) | AU2007278837A1 (enExample) |
| BR (1) | BRPI0714985A2 (enExample) |
| CA (1) | CA2658246A1 (enExample) |
| MX (1) | MX2009000792A (enExample) |
| WO (1) | WO2008014457A1 (enExample) |
| ZA (1) | ZA200900234B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109251155A (zh) * | 2017-07-14 | 2019-01-22 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5242950A (en) * | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| WO1996024346A1 (en) * | 1995-02-10 | 1996-08-15 | The University Of Toronto Innovations Foundation | Deprenyl compounds for treatment of glaucoma |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
-
2007
- 2007-07-27 AU AU2007278837A patent/AU2007278837A1/en not_active Abandoned
- 2007-07-27 EP EP07813482A patent/EP2046451A1/en not_active Ceased
- 2007-07-27 WO PCT/US2007/074603 patent/WO2008014457A1/en not_active Ceased
- 2007-07-27 CN CNA2007800283812A patent/CN101495185A/zh active Pending
- 2007-07-27 BR BRPI0714985-9A patent/BRPI0714985A2/pt not_active IP Right Cessation
- 2007-07-27 ZA ZA200900234A patent/ZA200900234B/xx unknown
- 2007-07-27 MX MX2009000792A patent/MX2009000792A/es not_active Application Discontinuation
- 2007-07-27 JP JP2009522019A patent/JP2009544740A/ja active Pending
- 2007-07-27 US US12/375,247 patent/US20110160308A1/en not_active Abandoned
- 2007-07-27 KR KR1020097002001A patent/KR20090034365A/ko not_active Withdrawn
- 2007-07-27 CA CA002658246A patent/CA2658246A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5165242B2 (ja) | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 | |
| KR102496234B1 (ko) | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 | |
| JP5650208B2 (ja) | 薬物嗜癖の治療および嗜癖関連行動を改善するための組成物 | |
| JP2007535552A5 (enExample) | ||
| Manickavasagam et al. | Critical assessment of implantable drug delivery devices in glaucoma management | |
| JP2017503835A (ja) | 眼球疾患治療のための組成物及び方法 | |
| JP2008505173A (ja) | 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物 | |
| JP2008538215A5 (enExample) | ||
| JP2006512318A5 (enExample) | ||
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| ES2819215T5 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| JP2021503449A (ja) | 眼障害の処置のための組成物及び方法 | |
| JP2024515826A5 (enExample) | ||
| US20100137342A1 (en) | Methods for treating vascular disruption disorders | |
| JP2009196973A (ja) | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 | |
| TW200944518A (en) | Multifunctional ophthalmic compositions | |
| EP3958839A1 (en) | Intracanalicular hydrogel inserts for the delivery of anesthetics | |
| JP2009544740A5 (enExample) | ||
| JP2023506838A5 (enExample) | ||
| WO2005067891A1 (en) | Compositions comprosing memantine and polyanionic polymers for administration to the eye | |
| JP4758581B2 (ja) | 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用 | |
| JP2010260857A (ja) | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 | |
| CN1170532C (zh) | 用于青光眼治疗的2-氨基1,2,3,4-四氢化萘衍生物 | |
| WO2006123675A1 (ja) | アミジノ誘導体を有効成分として含む神経細胞の保護剤 | |
| MY145266A (en) | Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |